Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL- BFM 90

Blood

Volumn 95, Issue 11, 2000, Pages 3310-3322

  Schrappe, Martin ^a   Reiter, Alfred ^b   Ludwig, Wolf Dieter ^b   Harbott, Jochen ^b   Zimmermann, Martin ^b   Hiddemann, Wolfgang ^b   Niemeyer, Charlotte ^b   Henze, Günter ^b   Feldges, Andreas ^b   Zintl, Felix ^b   Kornhuber, Bernhard ^b   Ritter, Jörg ^b   Welte, Karl ^b   Gadner, Helmut ^b   Riehm, Hansjörg ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DNA; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; IFOSFAMIDE; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; PREDNISONE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BRAIN METASTASIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOPHENOTYPING; INFANT; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADOLESCENT; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; CRANIAL IRRADIATION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOPHENOTYPING; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; PROGNOSIS; REGRESSION ANALYSIS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0034210549     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Riehm H, Gadner H, Henze G, et al. Results and significance of six randomized trials in four consecutive ALL-BFM trials. Hamatol Bluttransfus. 1990;33:439.
2. Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med. 1998;339:605.
3. Reiter A, Schrappe M, Ludwig W-D, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients: results and conclusions of the multicenter trial ALL-BFM 86. Blood. 1994;64:3122.
4. Pui C-H, Crist WM, Look AT. Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia. Blood. 1990; 76:1449.
5. Kersey JH. Fifty years of studies of the biology and therapy of childhood leukemia. Blood. 1997; 90:4243.
6. + childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome. Blood. 1998;92:2730.
7. Schrappe M, Beck J, Brandeis WE, et al. Die Behandlung der akuten lymphoblastischen Leukämie im Kindes-und Jugendalter: Ergebnisse der multizentrischen Therapiestudie ALL-BFM 81. Klin Padiatr. 1987;199:133.
8. Conter V, Arico M, Valsecchi MG, et al. Extended intrathecal MTX may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Munster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica. J Clin Oncol. 1995;13:2497.
9. Schorin MA, Blattner S, Gelber RD, et al. Results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. J Clin Oncol. 1994;12:740.
10. Tubergen DG, Gilchrist GS, O'Brien RT, et al. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial. J Clin Oncol. 1993; 11:527.
11. Gaynon PS, Steinherz PG, Bleyer WA, et al. Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Childrens Cancer Group Study CCG-106. J Clin Oncol. 1993;11: 2234.
12. Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med. 1998;338: 499.
13. Chessells JM, Bailey C, Richards SM. Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X. Medical Research Council Working Party on Childhood Leukaemia. Lancet. 1995;345:143.
14. Land VJ, Shuster JJ, Crist WM, et al. Comparison of two schedules of intermediate-dose MTX and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Clin Oncol. 1994;12:1939.
15. Nachman JB, Sather HN, Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998;338:1663.
16. Riehm H, Reiter A, Schrappe M, et al. Die Corticosteroid-abhängige Dezimierung der Leukämiezellzahl im Blut als Prognosefaktor bei der akuten lymphoblastischen Leukämie im Kindesalter (Therapiestudie ALL-BFM 83) [The in vivo response on corticosteroid therapy as an additional prognostic factor in childhood acute lymphoblastic leukemia (therapy study ALL-BFM 83)]. Klin Padiatr. 1987;199:151.
17. Gajjar A, Ribeiro R, Hancock ML, et al. Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. Blood. 1995;86:1292.
18. Steinherz PG, Gaynon PS, Breneman JC, et al. Cytoreduction and prognosis in acute lymphoblastic leukemia - the importance of early marrow response: report from the Childrens Cancer Group. J Clin Oncol. 1996;14:389.
19. Schrappe M, Reiter A, Riehm H. Cytoreduction and prognosis in childhood acute lymphoblastic leukemia [letter]. J Clin Oncol. 1996;14:2403.
20. Arico M, Basso G, Mandelli F, et al. Good steroid response in vivo predicts a favorable outcome in children with T-cell acute lymphoblastic leukemia. Cancer. 1995;75:1684.
21. Sackmann-Muriel F, Felice MS, Zubizarreta P, Chantada G, Barbieri MF, Rossi J. Improved outcome in higher-risk acute lymphoblastic leukemia with a hybrid (Berlin-Frankfurt-Münster/St Jude's) therapy. Int J Pediatr Hematol Oncol. 1996;3:439.
22. Gaynon PS, Desai AA, Bostrom BC, et al. Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review. Cancer. 1997;80:1717.
23. Kaspers GJ, Veerman AJ, Pieters R, et al. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood. 1997;90:2723.
24. Meadows AT, Robison LL, Neglia JP, Sather H, Hammond D. Potential long-term toxic effects in children treated for acute lymphoblastic leukemia. N Engl J Med. 1989;321:1830.
25. Pui CH, Behm FG, Raimondi SC, et al. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med. 1989; 321:136.
26. Rimm IJ, Li FC, Tarbell NJ, Winston KR, Sallan SE. Brain tumors after cranial irradiation for childhood acute lymphoblastic leukemia. Cancer. 1987;59:1506.
27. Packer RJ, Meadows AT, Rorke LB, Goldwein JL, D'Angio G. Long-term sequelae of cancer treatment on the central nervous system in childhood. Med Pediatr Oncol. 1987;15:241.
28. Ochs JJ. Neurotoxicity due to central nervous system therapy for childhood leukemia. Am J Pediatr Hematol Oncol. 1989;11:93.
29. Hitchcock-Bryan S, Gelber RD, Cassady JR, Sallan SE. The impact of induction anthracycline on long-term failure-free survival in childhood acute lymphoblastic leukemia. Med Pediatr Oncol. 1986;14:211.
30. Bennett JM, Catovski D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) cooperative group. Br J Haematol. 1976;33:451.
31. van der Does-van den Berg A, Bartram CR, Basso G, et al. Minimal requirements for the diagnosis, classification, and evaluation of the treatment of childhood acute lymphoblastic leukemia (ALL) in the "BFM Family" Cooperative Group. Med Pediatr Oncol. 1992;30:497.
32. Ludwig WD, Rieder H, Bartram CR, et al. Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: results of the German multicenter trials GMALL 03/87 and 04/89. Blood. 1998;92:1898.
33. Creutzig U, Harbott J, Sperling C, et al. Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM 87. Blood. 1995;86:3097.
34. Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995;9:1783.
35. Harbott J, Ritterbach J, Ludwig W-D, Bartram CR, Reiter A, Lampert F. Clinical significance of cytogenetic studies in childhood acute lymphoblastic leukemia: experience of the BFM trials. Recent Results Cancer Res. 1993;131:123.
36. Schlieben S, Borkhardt A, Reinisch I, et al. Incidence and clinical outcome of children with BCR/ ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM 90 and CoALL-05-92. Leukemia. 1996;10:957.
37. Hiddemann W, Wörmann B, Ritter J et al. Frequency and clinical significance of DNA aneuploidy in acute leukemia. Ann N Y Acad Sci. 1986; 468:227.
38. Langermann H-J, Henze G, Wulf M, Riehm H. Abschätzung der Tumorzellmasse bei der akuten lymphoblastischen Leukämie im Kindesalter: prognostische Bedeutung und praktische Anwendung. Klin Padiatr. 1982;194:209.
39. Buhrer C, Hartmann R, Fengler R, et al. Peripheral blast counts at diagnosis of late isolated bone marrow relapse of childhood acute lymphoblastic leukemia predict response to salvage chemotherapy and outcome. Berlin-Frankfurt-Munster Relapse Study Group. J Clin Oncol. 1996;14:2812.
40. Welte K, Reiter A, Mempel K, et al. A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Munster Study Group. Blood. 1996;87:3143.
41. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457.
42. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163.
43. Cox DR. Regression models and life tables. J Royal Stat Soc. 1972;34:187.
44. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley & Sons; 1980.
45. Ludwig W-D, Harbott J, Bartram CR, et al. Incidence and prognostic significance of immunophenotypic subgroups in childhood acute lymphoblastic leukemia: experience of the BFM study 86. Recent Results Cancer Res. 1993;131:269.
46. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996;14:18.
47. Riehm H, Gadner H, Henze G, Langermann H-J, Odenwald E. The Berlin childhood acute lymphoblastic leukemia therapy study, 1970-1976. Am J Pediatr Hematol Oncol. 1980;2:299.
48. Janka-Schaub GE, Harms D, Goebel U, et al. Randomized comparison of rotational chemotherapy in high-risk acute lymphoblastic leukaemia of childhood - follow up after 9 years. Coall Study Group. Eur J Pediatr. 1996;155:640.
49. Thyss A, Suciu S, Bertrand Y, et al. Systemic effect of intrathecal MTX during the initial phase of treatment of childhood acute lymphoblastic leukemia. The European Organization for Research and Treatment of Cancer Children's Leukemia Cooperative Group. J Clin Oncol. 1997;15:1824.
50. Janka-Schaub GE, Stührk H, Kortüm B, et al. Bone marrow blast count at day 28 as the single most important prognostic factor in childhood acute lymphoblastic leukemia. Hamatol Bluttransfus. 1992;34:233.
51. Pieters R, Huismans DR, Loonen AH, et al. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet. 1991;338:399.
52. Otten J, Suciu S, Lutz P, et al. The importance of L-asparaginase (A'ase) in the treatment of acute lymphoblastic leukemia (ALL) in children: results of the EORTC 58881 randomized phase III trial showing greater efficiency of Escherichia coli (E. coli) as compared to Erwinia (ERW) A'ase [abstract]. Blood. 1996;88:669a.
53. Conter V, Schrappe M, Arico M, et al. Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. J Clin Oncol. 1997; 15:2786.
54. Rivera GK, Raimondi SC, Hancock ML, et al. Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. Lancet. 1991;337:61.
55. Veerman AJ, Hahlen K, Kamps WA, et al. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol. 1996;14:911.
56. Mahoney DH Jr, Shuster JJ, Nitschke R, et al. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous MTX and intrathecal triple therapy - a Pediatric Oncology Group study. J Clin Oncol. 1998;16:1712.
57. Neglia JP, Meadows AT, Robison LL, et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;325:1330.
58. Ochs J, Mulhem R, Fairclough D, et al. Comparison of neuropsychologic functioning and clinical indicators of neurotoxicity in long-term survivors of childhood leukemia given cranial radiation or parenteral MTX: a prospective study. J Clin Oncol. 1991;9:145.
59. Waber DP, Tarbell NJ, Fairclough D, et al. Cognitive sequelae of treatment in childhood acute lymphoblastic leukemia: cranial radiation requires an accomplice. J Clin Oncol. 1995;13:2490.
60. Butler RW, Hill JM, Steinherz PG, Meyers PA, Finlay JL. Neuropsychological effects of cranial irradiation, intrathecal MTX, and systemic MTX in childhood cancer. J Clin Oncol. 1994;12:2621.
61. Niemeyer CM, Gelber RD, Tarbell NJ, et al. Low-dose versus high-dose MTX during remission induction in childhood acute lymphoblastic leukemia (Protocol 81-01 update). Blood. 1991;78:2514.
62. Frankel LS, Ochs J, Shuster JJ, et al. Therapeutic trial for infant acute lymphoblastic leukemia: the Pediatric Oncology Group experience (POG 8493). J Pediatr Hematol Oncol. 1997;19:35.
63. Silverman LB, McLean TW, Gelber RD, et al. Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium. Cancer. 1997;80: 2285.
64. Rubnitz JE, Downing JR, Pui CH, et al. TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance. J Clin Oncol. 1997;15:1150.
65. Borkhardt A, Cazzaniga G, Viehmann S, et al. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Blood. 1997;90:571.
66. Takeuchi S, Bartram CR, Miller CW, et al. Acute lymphoblastic leukemia of childhood: identification of two distinct regions of deletion on the short arm of chromosome 12 in the region of TEL and KIP1 Blood. 1996;87:3368.
67. Rubnitz JE, Behm FG, Pui CH, et al. Genetic studies of childhood acute lymphoblastic leukemia with emphasis on p16, MLL, and ETV6 gene abnormalities: results of St Jude Total Therapy Study XII. Leukemia. 1997;11:1201.
68. Sauerbrey A, Stammler G, Zintl F, Volm M. Expression and prognostic value of the retinoblastoma tumour suppressor gene (RB-1) in childhood acute lymphoblastic leukaemia. Br J Haematol. 1996;94:99.
69. Ribeiro RC, Broniscer A, Rivera GK, et al. Philadelphia chromosome-positive acute lymphoblastic leukemia in children: durable responses to chemotherapy associated with low initial white blood cell counts. Leukemia. 1997;11: 1493.
70. Coustan-Smith E, Behm FG, Sanchez J, et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet. 1998;351:550.
71. Yokota S, Hansen-Hagge TE, Ludwig W-D, et al. Use of polymerase chain reactions to monitor minimal residual disease in acute lymphoblastic leukemia patients. Blood. 1991;77:331.
72. Roberts WM, Estrov Z, Ouspenskaia MV, Johnston DA, McClain KL, Zipf TF. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. N Engl J Med. 1997;336:317.
73. van Dongen JJM, Seriu T, Panzer-Grumayer ER, et al. Prognostic value of minimal residual disease in childhood acute lymphoblastic leukemia: a prospective study of the International BFM Study Group. Lancet. 1998;352:1731.